Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study

Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study

scientific article

Author/s

Work details

Publication date: March 5, 2013

Language: English

Country of origin: Unknown

Copyright status

Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.

To learn more about copyright terms in different countries, visit the countries and terms page.